Company news
Nuformix PLC news in 2025
Nuformix PLC's news releases, calls and decks from 2025, newest first.
Update re. US FDA ODD Application
November 12, 2025
Underwritten Open Offer
October 28, 2025
Change of Auditor
October 10, 2025
European Respiratory Society Congress Attendance
September 25, 2025
US FDA ODD Application Submitted for NXP002
August 11, 2025
Confirmation of European ODD for NXP002
May 29, 2025
Publication of a Prospectus
May 23, 2025
£210,000 Placing
May 22, 2025
Attendance at American Thoracic Society Congress
May 19, 2025
Half-year Report
May 2, 2025
Confirmation of European Orphan Drug Designation
April 30, 2025
Change of Registered Office and Company Secretary
April 29, 2025
Correction - Exercise of Warrants
April 14, 2025
NXP002 Update
April 9, 2025
£168,750 Placing
January 30, 2025
Annual Results for period ended 30 September 2024
January 29, 2025
NXP002 ODD Application Submitted
January 28, 2025
NXP002 Orphan Drug Designation Draft Application
January 13, 2025